In 2022 & 2023, market players expected to sail in rough waters; might incur losses due to huge gap in currency translation followed by contracting revenues, shrinking profit margins & cost pressure on logistics and supply chain. Further, U.S. economy is expected to grow merely by 3% in 2022. Purchasing power in the country is expected to fell nearly by 2.5%.
On the other hand, European countries to see the worst coming in the form of energy crisis especially in upcoming winters!! Right after COVID-19, inflation has started gripping the economies across the globe. Higher than anticipated inflation, especially in western world had raised concerns for national banks and financial institutions to control the economic loss and safeguard the interest of the businesses. Increased interest rates, strong USD inflated oil prices, looming prices for gas and energy resources due to Ukraine-Russia conflict, China economic slowdown (~4% in 2022) disrupting the production and global supply chain and other factors would impact each industry negatively.
The United States Food and Drug Administration granted approval to Reblozyl, which is the first therapy for the treatment of patients with anemia/lack of blood cells in November 2019.
The aim of this therapy is to decrease the requirement of blood transfusions among patients.
The global post-hemorrhagic anemia treatment market is estimated to garner a sizeable revenue and grow at a robust CAGR over the forecast period, i.e., 2022 – 2030. The growth of the market can be attributed to the growing number of trauma cases across the globe, and increasing prevalence of bleeding disorders, such as hemophilia and Von Willebrand disease. In 2020, approximately 210,000 people in the world suffered from hemophilia, and about 84,000 were diagnosed with Von Willebrand disease. Along with these, rise in awareness levels regarding anemia, and escalating technological developments in the pharmaceutical sector, especially in developed and developing nations. Furthermore, surge in the percentage of population with a family history of anemia and blood diseases is projected to elevate the total number of cases of acute post-hemorrhagic anemia. This in turn is predicted to offer abundant growth opportunities to the market in the near future.
Get more information on this report: Download Sample PDF
The market is segmented by treatment into blood transfusion, surgery, iron supplements, extra oxygen, fluids, and others, out of which, the blood transfusion segment is anticipated to hold the largest share in the global post-hemorrhagic anemia treatment market. As a patient suffering from this type anemia quickly loses a large amount of blood, performing a blood transfusion becomes a necessity. This is assessed to be a major factor to boost the growth of the market segment in the future. Additionally, on the basis of end user, the hospitals segment is evaluated to occupy the largest share during the forecast period, which can be ascribed to the high preference of patients to get treatment from a medical professional in a hospital facility. Apart from this, increase in number of patient admissions in hospitals is also forecasted to bolster the segment growth in the years to come.
According to the statistics by the World Health Organization, the global per capita healthcare expenditure amounted to USD 1,064.741 in the year 2017. The worldwide healthcare expenditure per person grew from USD 864.313 in 2008 to USD 1,110.841 in 2018, where the U.S. is the top country that amounted to healthcare expenditure of USD 10, 623.85 per capita in 2018. As of 2018, the domestic general government healthcare spending in the U.S. was USD 5355.79, which grew from USD 3515.82 in 2008. These are some of the factors responsible for market growth over the past few years. Moreover, as per the projections by the Centers for Medicare & Medicaid Services (CMS), the estimated average annual percent change related to National Health Expenditures (NHE) in the U.S. was 5.2% in 2020 as compared to 2019 (4.5%). Furthermore, the National Health Expenditures are projected to reach USD 6,192.5 Billion in 2028, where the per capita expenditure is estimated to touch USD 17,611 in the same year. These are notable indicators that are anticipated to create lucrative business opportunities in upcoming years.
On the basis of geographical analysis, the global post-hemorrhagic anemia treatment market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and the Middle East & Africa region. The market in Asia Pacific is estimated to witness noteworthy growth over the forecast period on the back of the high number of patients, and rising government focus to improve healthcare infrastructure in the region. Moreover, the market in North America is expected to acquire the largest share by the end of 2030, which can be credited to the high healthcare spending, and availability of well-established medical facilities in the region. According to the Centers for Medicare and Medicaid Services, U.S. health care spending reached USD 3.8 trillion or USD 11,582 per person in 2019. As a share of the nation's Gross Domestic Product, health spending accounted for 17.7 percent that year. In addition, strong footprint of major market players is also predicted to propel the market growth in the region in the coming years.
The global post-hemorrhagic anemia treatment market is further classified on the basis of region as follows:
Our in-depth analysis of the global post-hemorrhagic anemia treatment market includes the following segments:
Ans: The major factors driving market growth are growing number of trauma cases across the globe, and increasing prevalence of bleeding disorders.
Ans: The market is anticipated to attain a robust CAGR over the forecast period, i.e., 2022 – 2030.
Ans: Asia Pacific will provide more business opportunities for market growth owing to the high number of patients, and rising government focus to improve healthcare infrastructure in the region.
Ans: The major players in the market are Rockwell Medical Inc., Amgen Inc., Vifor Pharma Management Ltd., F. Hoffmann-La Roche Ltd, Pfizer Inc., and others.
Ans: The company profiles are selected based on the revenues generated from the product segment, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.
Ans: The market is segmented by treatment, end user, and by region.
Ans: The hospitals segment is anticipated to hold largest market size and is estimated to grow at a notable CAGR over the forecast period and display significant growth opportunities.
Ans: Lack of skilled medical professionals in underdeveloped countries is estimated to hamper the market growth.